Supplementary tables

Table S1. PRISMA Checklist.

		TITLE	
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
		ABSTRACT	
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	1
		INTRODUCTION	
Rationale	3	Describe the rationale for the review in the context of what is already known.	2
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	3
	-	METHODS	
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	3
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	3
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	3
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Supple- mentary fie 2

Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	3
Data collection pro- cess	in dublicate) and any processes for optaining and confirming data from investiga-		3
Data items	1 1	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	3
RICK OF DISC ID IDGIVIG- 1		Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	4
Summary measures	1 3	State the principal summary measures (e.g., risk ratio, difference in means).	NA
Synthesis of results	Describe the methods of handling data and combining results of stud 4 cluding measures of consistency (e.g., l²) for each meta-ana		NA
Risk of bias across studies	1 5	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	NA
Additional analyses	1 6	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	NA
RESULTS			
Study selection	1 7	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	4
Study characteristics	characteristics 1 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.		4
Risk of bias within studies	1 9	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	4
Results of individual studies	2	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	4-7

Synthesis of results	2 1	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	NA
Risk of bias across studies	2 2	Present results of any assessment of risk of bias across studies (see Item 15).	18-1
Additional analysis		Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	NA
DISCUSSION			
Summary of evidence	2 4	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	7-8
Limitations	2 5	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	9
Conclusions	2 6	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	9
FUNDING			
Funding	2 7	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	10

File S2. Search strategy. Number of results on pubmed: 3579 titles.

(coronavirus 2019[tw] OR nouveau coronavirus[tw] OR corona virus 2019[tw] OR coronavirus disease 2019[tw] OR coronavirus disease 2019[tw] OR coronavirus pandemic[tw] OR corona virus pandemic[tw] OR coronavirus crisis[tw] OR corona virus outbreak[tw] OR coronavirus crisis[tw] OR "coronavirus disease -19"[tw] OR "corona virus disease -19"[tw] OR coronavirus epidemic[tw] OR coronavirus epidemic[tw] OR coronavirus disease -19"[tw] OR novel coronavirus[tw] OR new coronavirus[tw] OR new coronavirus[tw] OR new coronaviruses[tw] OR covid-19[tw] OR covid-19 pandemic[tw] OR covid-19 virus[tw] OR covid-19 virus[tw] OR covid-19 virus[tw] OR covid-19 virus infection*[tw] OR severe acute respiratory syndrome coronavirus 2[tw] OR SARS-CoV-2[tw] OR SARS coronavirus 2[tw] OR SARS-CoV-2 infection*[tw] OR nCoV OR "2019 - nCoV"[tw] OR "2019 - nCoV disease"[tw] OR "2019 - nCoV infection"[tw]) AND

(Immunization[Mesh] OR immuni*[tw] OR Vaccines[Mesh] OR Vaccination[Mesh] OR vaccin*[tw] OR "Papillomavirus Vaccines" [Mesh] OR Papillomavirus[tw] OR "Papillomavirus" [Tw] OR "Papillomavirus" [Tw lomaviridae" [Mesh] OR HPV[tw] OR "wart virus" [tw] OR "Warts" [Mesh] OR "wart virus"[tw] OR "Condylomata Acuminata"[Mesh] OR "Measles-Mumps-Rubella Vaccine" [Mesh] OR MMR[tw] OR "Measles" [Mesh] OR "Measles virus" [Mesh] OR "Measles Vaccine"[Mesh] OR mumps*[tw] OR Mumps[Mesh] OR "Mumps virus"[Mesh] OR "Mumps Vaccine" [Mesh] OR Rubella [Mesh] OR "Rubella virus" [Mesh] OR "Rubella Vaccine" [Mesh] OR varicella [tw] OR "Chickenpox" [Mesh] OR "Chickenpox Vaccine" [Mesh] OR zoster[tw] OR "Herpes Zoster" [Mesh] OR "Herpes Zoster Vaccine" [Mesh] OR "Diphtheria-Tetanus Vaccine" [Mesh] OR tetanus [tw] OR "Diphtheria-Tetanus-Pertussis Vaccine" [Mesh] OR Tetanus [Mesh] OR "Tetanus Toxoid" [Mesh] OR "Diphtheria-Tetanusacellular Pertussis Vaccines" [Mesh] OR "Whooping Cough" [Mesh] OR Diphtheria [Mesh] OR vzv[tw] OR "Bordetella pertussis" [Mesh] OR "Haemophilus Vaccines" [Mesh] OR pertusis[tw] OR tdap[tw] OR "Meningococcal Infections" [Mesh] OR meningococcal[tw] OR "Meningitis, Meningococcal" [Mesh] OR "Meningococcal Vaccines" [Mesh] OR mcv[tw] OR "Meningitis, Pneumococcal" [Mesh] OR "Pneumococcal Infections" [Mesh] OR "Pneumococcal Vaccines" [Mesh] OR "Hepatitis A" [Mesh] OR "Hepatitis A Vaccines" [Mesh] OR "Hepatitis B"[Mesh] OR "Hepatitis B Vaccines"[Mesh] OR "Hepatitis C"[Mesh] OR polio[tw] OR Poliomyelitis[Mesh] OR "Poliovirus Vaccines"[Mesh] OR "Rotavirus Infections"[Mesh] OR Rotavirus[Mesh] OR "Rotavirus Vaccines"[Mesh] OR "typhoid vaccine"[tw] OR "Typhoid-Paratyphoid Vaccines"[Mesh] OR typhoid[tw] OR "Typhoid Fever" [Mesh] OR influenza [tw] OR "Influenza, Human" [Mesh] OR "Influenza Vaccines" OR "BCG Vaccine" OR "Bacterial Vaccines" [Mesh] OR "Vaccine-Preventable Diseases" [Mesh] OR "Immunization Programs" [Mesh] OR immunization campaign*[tw] OR immunization promotion[tw] OR immunization awareness[tw] OR routine immunization*[tw] OR routine vaccin*[tw] OR catch-up immunization*[tw] OR "Immunization Schedule"[Mesh] OR vaccination schedule[tw] OR "Vaccination Coverage"[Mesh] OR mop-up campaign*[tw] OR Global Polio Eradication Initiative OR Polio eradication initiative*[tw] OR "Mass Vaccination"[Mesh] OR expanded program* on immunization[tw] OR EPI[tw])